HAE (Haemonetics) Long-Term Debt : $1,220 Mil (As of Sep. 2024)

View and export this data going back to 1991. Start your Free Trial

What is Haemonetics Long-Term Debt?

Haemonetics's Long-Term Debt for the quarter that ended in Sep. 2024 was $1,220 Mil.

Haemonetics's quarterly Long-Term Debt increased from Mar. 2024 ($798 Mil) to Jun. 2024 ($1,218 Mil) and increased from Jun. 2024 ($1,218 Mil) to Sep. 2024 ($1,220 Mil).

Haemonetics's annual Long-Term Debt increased from Mar. 2022 ($559 Mil) to Mar. 2023 ($754 Mil) and increased from Mar. 2023 ($754 Mil) to Mar. 2024 ($798 Mil).

Haemonetics Long-Term Debt Historical Data

The historical data trend for Haemonetics's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Haemonetics Long-Term Debt Chart

Haemonetics Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Long-Term Debt

Get a 7-Day Free Trial

305.51

690.59

559.44

754.10

797.56

Haemonetics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Long-Term Debt	Get a 7-Day Free Trial															748.66	856.85	797.56	1,218.48	1,219.52

Haemonetics (NYSE:HAE) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Haemonetics Long-Term Debt Related Terms

Thank you for viewing the detailed overview of Haemonetics's Long-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Haemonetics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Haemonetics Corp (NYSE:HAE) » Definitions » Long-Term Debt

Comparable Companies

Traded in Other Exchanges

HAZ:Germany HAZ:Germany

Address

125 Summer Street, Boston, MA, USA, 02110

Website

https://www.haemonetics.com

Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company places primary emphasis on its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.

Executives

Stewart W Strong	officer: President, Global Hospital	C/O HAEMONETICS CORPORATION, 125 SUMMER STREET, BOSTON MA 02110
Anila Lingamneni	officer: EVP, Chief Technology Officer	HAEMONETICS CORPORATION, 125 SUMMER STREET, BOSTON MA 02110
Michelle L Basil	officer: EVP and General Counsel	HAEMONETICS CORPORATION, 400 WOOD ROAD, BRAINTREE MA 02184
Josep Llorens	officer: EVP, Global Manufacturing	HAEMONETICS CORPORATION, 400 WOOD ROAD, BRAINTREE MA 02184
Charles J Dockendorff	director	COVIDIEN LTD., 15 HAMPSHIRE STREET, MANSFIELD MA 02048
Diane M Bryant	director	2200 MISSION COLLEGE BLVD, SANTA CLARA CA 95054
Farris Maryanne Maunsell	officer: VP, Chief Accounting Officer	C/O HAEMONETICS CORPORATION, 125 SUMMER STREET, BOSTON MA 02110
Roy Galvin	officer: President, Global Plasma & BC	C/O HAEMONETICS CORPORATION, 125 SUMMER STREET, BOSTON MA 02110
Laurie A. Miller	officer: SVP, Human Resources	C/O HAEMONETICS CORPORATION, 125 SUMMER STREET, BOSTON MA 02110
Mark W Kroll	director	PO BOX 23, CRYSTAL BAY MN 55323
Dan Goldstein	officer: VP, Corporate Controller	HAEMONETICS CORPORATION, 400 WOOD ROAD, BRAINTREE MA 02184
Christopher Simon,	director, officer: President & CEO	HAEMONETICS CORPORATION, 400 WOOD ROAD, BRAINTREE MA 02184
James Darecca	officer: EVP, Chief Financial Officer	C/O HAEMONETICS CORPORATION, 125 SUMMER STREET, BOSTON MA 02110
Burke William P. Mr.	officer: EVP, Chief Financial Officer	HAEMONETICS CORPORATION, 400 WOOD ROAD, BRAINTREE MA 02184
Lloyd Emerson Johnson	director	16737 NEW PROVIDENCE LANE, CHARLOTTE NC 28277